The early development of neutralizing ADAs in most participants, together with the low doses assessed in the study, might have impacted the opportunity to observe clinical activity with the molecule, even though preclinical data for TYRP1-TCB demonstrated tumor shrinkage (18). This evidence concerns the gene TYRP1 and neoplasm.